{"id":"antiandrogen-docetaxel","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Nausea/vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"50-80","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The antiandrogen component antagonizes androgen receptor signaling, which is critical for prostate cancer cell growth and survival. Docetaxel, a taxane chemotherapy agent, stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. Together, these agents target complementary pathways in hormone-sensitive and castration-resistant prostate cancer.","oneSentence":"This combination blocks androgen signaling while simultaneously disrupting microtubule dynamics to inhibit cancer cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:45.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"},{"name":"Metastatic hormone-sensitive prostate cancer (mHSPC)"}]},"trialDetails":[{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03456843","phase":"PHASE2","title":"Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2018-03-20","conditions":"Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":190},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT00309985","phase":"PHASE3","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-09-26","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":790},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT07172685","phase":"NA","title":"Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-30","conditions":"Prostate Cancer","enrollment":116},{"nctId":"NCT06687421","phase":"","title":"Implementation of Precision Medicine in High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Andreas Josefsson","startDate":"2024-06-10","conditions":"Prostate Cancer","enrollment":5500},{"nctId":"NCT03641560","phase":"PHASE4","title":"A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-09-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":52},{"nctId":"NCT06446401","phase":"","title":"The Case of \"Triple\" Versus \"Double\" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-10-20","conditions":"Prostate Cancer","enrollment":1400},{"nctId":"NCT05676203","phase":"PHASE3","title":"A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2023-05-16","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":250},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT06498921","phase":"","title":"An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-15","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":106},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT03066154","phase":"PHASE1","title":"Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2016-09","conditions":"Prostatic Neoplasms","enrollment":24},{"nctId":"NCT06350825","phase":"PHASE3","title":"Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-01-01","conditions":"Metastatic Prostate Cancer, Therapy, Directly Observed","enrollment":200},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":960},{"nctId":"NCT00651326","phase":"PHASE3","title":"Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-06-02","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT04800146","phase":"","title":"A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study","status":"COMPLETED","sponsor":"Ilaria Colombo","startDate":"2021-02-25","conditions":"Covid19, Cancer","enrollment":177},{"nctId":"NCT03879122","phase":"PHASE2, PHASE3","title":"A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer","status":"UNKNOWN","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2019-02-11","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":135},{"nctId":"NCT00288080","phase":"PHASE3","title":"Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-12","conditions":"Prostate Cancer","enrollment":612},{"nctId":"NCT03061643","phase":"PHASE2","title":"An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2017-02-08","conditions":"Prostatic Neoplasm","enrollment":42},{"nctId":"NCT02376296","phase":"","title":"Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients","status":"COMPLETED","sponsor":"Saladax Biomedical, Inc.","startDate":"2015-02","conditions":"Prostate Cancer","enrollment":35},{"nctId":"NCT03119857","phase":"PHASE3","title":"Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14","status":"UNKNOWN","sponsor":"Göteborg University","startDate":"2009-02","conditions":"Prostatic Neoplasms","enrollment":349},{"nctId":"NCT00104715","phase":"PHASE3","title":"Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2004-10-18","conditions":"Prostate Cancer","enrollment":385},{"nctId":"NCT03827473","phase":"PHASE2","title":"Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"University of Utah","startDate":"2019-02-08","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer","enrollment":1},{"nctId":"NCT00528866","phase":"PHASE2","title":"Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT00392938","phase":"","title":"Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-12","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere"],"phase":"phase_3","status":"active","brandName":"Antiandrogen+docetaxel","genericName":"Antiandrogen+docetaxel","companyName":"Göteborg University","companyId":"g-teborg-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks androgen signaling while simultaneously disrupting microtubule dynamics to inhibit cancer cell proliferation and survival. Used for Metastatic castration-resistant prostate cancer (mCRPC), Metastatic hormone-sensitive prostate cancer (mHSPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}